Christina Weng, MD, FAAD

Qing Yu Christina Weng is a physician-scientist, entrepreneur, and biotech executive. She is the Chief Medical Officer of Pelage Pharmaceuticals, a biotech developing innovative treatments for hair loss by targeting stem cell metabolism. Prior to Pelage, Christina led business development and strategy at Kira Pharmaceuticals, a global company developing complement therapeutics. Christina co-founded Mymiel, a high-performance clean skincare line, where she served as Chief Strategy Officer. As faculty at Harvard Medical School and attending dermatologist at the Massachusetts General Hospital, she specializes in melanoma and pigmentary disorders. She is on the Board of Directors for the Dermatology Innovation Forum and the Dermatology Summit. She is on the Advisory Board for Immunis, a regenerative medicine company developing secretomes for age-related dysfunction.

Christina attended the California Institute of Technology, where she received her bachelor’s degrees in Biology and English with honors. She graduated Magna Cum Laude from Harvard Medical School, where she received her medical degree and was a fellow of the Howard Hughes Medical Institute. She completed dermatology residency at the Harvard Combined Dermatology Residency Training Program with advanced clinical training at the MGH Laser & Cosmetics Center. Her postdoctoral bench research was at the Cutaneous Biology Research Center of MGH. Her clinical research has led to new guidelines recommended by the American Academy of Dermatology for drug monitoring. She has received research grants and awards from the Howard Hughes Medical Institute, American Skin Association, American Dermatological Association, and National Institutes of Health. She holds multiple patents.